A Presurgical Study To Evaluate Molecular Changes That Occur In Human Non-Small Cell Lung Cancer Tissue After Short Term Exposure To PF-00299804.
Phase of Trial: Phase I
Latest Information Update: 21 Jun 2012
At a glance
- Drugs Dacomitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 21 Jun 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 21 Jun 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.